RxDoctor Payments Data

Ken Chiu, MD

Endocrinology, Diabetes & Metabolism · Duarte, CANPI 1639126691

Payments from drug & device makers

$3,718in general payments, 2019–2025

Across 67 payments — averaging $55.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$2K
  • Abbott$496
  • Novo Nordisk$387
  • Lilly USA, LLC$302
  • Corcept Therapeutics$143
  • Janssen Scientific Affairs, LLC$123
  • plus $268 from 9 others

What the payments were for

  • Food & beverage$1,66297%
  • Education$563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,718 in reported general payments places this provider in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$29,509
Medicare patients
91
Services billed
204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide257$295,189
TrulicityDulaglutide87$132,802
JardianceEmpagliflozin69$102,802
FarxigaDapagliflozin Propanediol35$51,057
Tresiba Flextouch U-100Insulin Degludec80$46,910
TradjentaLinagliptin37$42,423
MounjaroTirzepatide31$41,269
Tresiba Flextouch U-200Insulin Degludec19$26,533
JanuviaSitagliptin Phosphate19$22,507
RybelsusSemaglutide19$22,316
Repatha SureclickEvolocumab18$11,937
Gvoke Hypopen 2-PackGlucagon12$10,879
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$9,140
Nano 2nd Gen Pen NeedlePen Needle, Diabetic51$3,895
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$387$317,505276 claims
Lilly USA, LLCTrulicity, Mounjaro$302$174,071118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Duarte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →